分子标志物引领下的恶性肿瘤靶向治疗.pptVIP

An overview of the phase III trial design – phase III results are given at the beginning of the presentation for maximum impact. This gives an overview of the excellent efficacy results for Avastin + IFL - all efficacy endpoints were significantly improved in the Avastin arm This slide emphasises the highly significant improvement in overall survival, which was the primary endpoint of the study, with separation between the two groups from very early on in the study. Endostatin 复性是一个世界性难题。超过 99% 的 Endostatin 不能复性 Ⅲ 期 临 床 试 验 两组患者的临床症状缓解率比较 临床症状 NP＋恩度 NP+安慰剂 P值 咳嗽(%) 71.36 61.02 0.0527 咳痰(%) 68